Nov 12023

AI-Powered Drug Discovery Efforts Could Lead to New Treatments

Stephen Abreu
, , , ,

Stephen Abreu, Sidley partner, talks to Colin Hill, CEO and Co-Founder of AI-powered drug discovery company Aitia, about how the use of AI is revolutionizing the biotech space.

Colin Hill explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative and predictive understanding of the actions of biological systems. This has very practical implications for oncology and new treatments for Parkinson’s and Alzheimer’s.

They also discuss how AI can be deployed on “undruggable” targets, and how the Aitia “Digital Twins” technology can be utilized with the goal of discovering novel combinations of drug targets.

“State of the Art”: – AI Use in Drug Discovery from Sidley Austin LLP on Vimeo.

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.

Stephen Abreu

San Francisco

sabreu@sidley.com

You might also like
New Guidance on Parallel Import Licensing Applicable to Northern Ireland Under the Windsor Framework

Brexit brought new challenges to the pharmaceutical industry, one of them being the special situation of Northern Ireland (NI), which, although part of the UK, remained subject to EU law under the NI Protocol. Pharmaceutical products placed on the NI market had to comply with EU law. For import purposes this created de facto an EU border between NI and the rest of the UK (namely England, Wales, and Scotland). The Windsor Framework provides a new set of arrangements to restore the smooth flow of trade within the UK.

Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs

Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance.

Life Sciences Companies with Operations in EU Could Be Affected by ESG Law

EU member states are beginning to implement EU environmental, social, and governance (ESG) legislation into national law, meaning life sciences companies will need to look at its impact on their global supply chains, including for APIs. Michele Tagliaferri, Anna-Shari Melin, and Nadja Schwarz explain.